Diastolic Function Assessment With Cardiac Magnetic Resonance Imaging
NCT ID: NCT05438030
Last Updated: 2023-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
37 participants
INTERVENTIONAL
2022-09-01
2024-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators wish to investigate how to best make measurements using CMR to identify those with impaired diastolic function, in the context of the current gold standard test (echocardiography).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cardiac Magnetic Resonance Tomography for Heart Failure With Preserved Ejection Fraction
NCT05322109
Cardiac Magnetic Resonance Assessment for Heart Failure With Preserved Ejection Fraction
NCT04063579
Understanding the Mechanisms of Diastolic Dysfunction
NCT03340233
Validation of CMR Against Invasive Haemodynamics in Patients With HFpEF
NCT03251183
Diffusion MRI in Heart Failure
NCT02973633
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The diseased cohort will comprise patients with preserved systolic function and known raised B-type natriuretic peptide levels (BNP, a blood test indicating raised pressures in the heart) from cardiology clinics who are undergoing a clinical CMR scan.
The healthy controls will comprise patients also undergoing MRI scans, but who are strongly expected not to have heart diastolic disease - for example, patients undergoing MRI scans for family screening but displaying no symptoms or other abnormal tests. BNP blood testing will not be necessary for the healthy control arm.
If a participant in the health control arm is found to have diastolic dysfunction, they will be eligible to cross over to the diseased group, after discussing their results with their physician. At this point, a BNP level will be checked if the patient is happy to continue in the study. The criteria for crossover this will be Grade 2 or greater diastolic dysfunction as per the British Society of Echocardiography Diastolic Dysfunction guidelines. If the BNP level is not raised, despite meeting imaging criteria for diastolic dysfunction, the patient will not be eligible for the full analysis and the second visit will not be performed.
Patients in the diseased cohort will represent a range of pathologies that typically cause HFPEF (heart failure with preserved ejection fraction), including hypertrophic cardiomyopathy, aortic stenosis, and cardiac amyloidosis.
On the same day as their clinical CMR scan, participants will undergo a focused research echocardiogram which will include quantification of left atrium size, trans-mitral Doppler, tissue Doppler imaging and global longitudinal strain (GLS). All measurements will be performed in both left lateral decubitus positioning (typical for echocardiography) and supine positioning (typical for CMR).
Participants will then undergo their clinical CMR scan.
After their CMR scan, patients will then undergo repeat focused echocardiography.
When patients return for their clinical follow-up, they will undergo a repeat focused echocardiogram and 15-minute research CMR scan.
This design allows the agreement between each CMR and echocardiographic measure of diastolic function to be assessed. More importantly, this agreement can be described in the context of:
1. Changes in diastolic function parameters due to patient positioning
2. Changes in diastolic function parameters during a scan, e.g. due to the patient relaxing
3. Each modality's test re-test reproducibility over two timescales (less than 1 hour versus several weeks).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Paired cardiac MRI and echocardiographic measurements
Cardiac MRI scan
Undertaken at the radiology department at Hammersmith Hospital. The scan will be performed by the MRI radiographers, under the supervision of a consultant radiologist or cardiologist.
Echocardiogram scan
Undertaken at the Peart Rose research unit, by a British Society of Echocardiography accredited sonographer.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cardiac MRI scan
Undertaken at the radiology department at Hammersmith Hospital. The scan will be performed by the MRI radiographers, under the supervision of a consultant radiologist or cardiologist.
Echocardiogram scan
Undertaken at the Peart Rose research unit, by a British Society of Echocardiography accredited sonographer.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cohort 2: patients without grade 2 or more diastolic dysfunction on echocardiography.
Exclusion Criteria
* Contraindications to gadolinium contrast agents - for safety.
* Severe claustrophobia - extra CMR scanning may prove too difficult.
* Pregnancy - likely to be undergoing progressive physiological changes in the conduct of the study which may invalid assumptions about repeat scanning.
* The ability to provide informed consent.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Imperial College London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hammersmith Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21HH7048
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.